NICE evaluated Axonics sacral neuromodulation system for treating refractory overactive bladder

15

Sep 2020

On September 03, 2020, the National Institute for Health and Care Excellence (NICE) issued medical technologies guidance on Axonics sacral neuromodulation (SNM) system for treating refractory overactive bladder.

Axonics SNM system consists of the following parts:

  • Pulse generator that implanted subcutaneously in the upper buttock
  • Lead electrodes implanted through the corresponding sacral foramen that provides electrical impulses to the sacral nerves
  • Rechargeable battery
  • A handheld remote control that activates the stimulator, adjusts the amplitude, and checks the battery status
  • The wireless charger, attachable to the skin over the implanted stimulator

The innovative aspects of the Axonics SNM system are:

  • The long-expected life span of rechargeable battery - at least 15 years, which is longer than the comparable non-rechargeable device
  • Compatibility with MRI
  • Smaller size comparing with existing non-rechargeable SNM devices, making it more suitable for people with a low body mass index

The Axonics SNM device costs £9,660 for the permanent implant.

NICE concluded that evidence supports the case for adopting the Axonics sacral neuromodulation (SNM) system for treating refractory overactive bladder in the NHS, as it improves symptoms and quality of life. It also has a longer battery life than the non-rechargeable system used in NHS clinical practice.

NICE recommended considering the Axonics SNM system as an option when conservative or pharmacological treatment has not worked (in line with NICE's guidelines on urinary incontinence and pelvic organ prolapse, and lower urinary tract symptoms).

The cost analysis showed that using the Axonics SNM system may lead to cost savings if the battery is expected to last at least six years. Cost modeling estimates that over 15 years, the Axonics SNM system is cost-saving compared with the non-rechargeable system by about £6,025 per person.

See the full guidance here

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more